Market Overview

The global antipsychotic drugs market was valued at USD 18.04 billion in 2023 and is expected to reach around USD 37.40 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2032. This growth is driven by an increasing number of patients with mental health disorders, advancements in drug formulations, and rising awareness of mental health treatment options.

Download a sample of this report @ https://www.towardshealthcare.com/personalized-scope/5147

Key Market Insights

Dominance of Second-Generation Antipsychotics: In 2023, second-generation antipsychotic drugs held a 65% market share due to their effectiveness and fewer side effects compared to first-generation antipsychotics.

Schizophrenia Treatment Leads the Market: Schizophrenia was the most treated disorder with antipsychotic drugs, accounting for a 52% market share in 2023. The rising number of schizophrenia patients is a significant growth driver.

North America as a Market Leader: North America led the market in 2023 with a 37% share, supported by a high prevalence of mental disorders, robust healthcare infrastructure, and strong market presence of leading pharmaceutical companies.

Key Factors Driving Market Growth

• Increasing Prevalence of Mental Health Disorders: An estimated 24 million people globally suffer from schizophrenia, accounting for approximately 0.32% of the world’s population. Schizophrenia is a major disability due to its impact on daily living, as evidenced by studies like those from the Danish national health registries, which highlight its significant burden on individuals and populations.
• Rising Mental Health Awareness and Treatments: Between 2019 and 2021, the percentage of U.S. adults receiving mental health treatment increased from 19.2% to 21.6%. Factors contributing to this rise include reduced stigma, expanded insurance coverage, and the growing prevalence of teletherapy.
• Boost in Clinical Trials and Research: Clinical trials conducted by the National Institute of Mental Health and other organizations are crucial in driving innovation and expanding treatment options for patients with schizophrenia and other mental health conditions.
• Increased Product Approvals: Recent approvals of new drugs, such as Pimavanserin and KarXT, have contributed to market expansion by providing more effective treatment options with improved safety profiles.

Challenges Impacting Market Growth

• Adverse Effects of Antipsychotic Drugs: Side effects like tardive dyskinesia, weight gain, and sleepiness can discourage patients from adhering to their medication regimens, leading to symptom relapse and increased healthcare costs.

Regional Market Insights

• North America: Dominates the market due to high disease prevalence, significant healthcare spending, and extensive insurance coverage for mental health services. Government initiatives to raise mental health awareness further support market growth.

Key Companies in the Antipsychotic Drugs Market

• Otsuka Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Dr. Reddy’s Laboratories Limited
• AstraZeneca PLC.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Pfizer Inc.
• Alkermes Plc.
• AbbVie Inc. (Allergan Inc.)
• Bristol-Myers Squibb

Market Segmentation

• By Therapeutic Class: First Generation, Second Generation
• By Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, Other Applications
• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• By Geography: North America, Europe, Asia Pacific, Middle East and Africa, South America

Read Also: https://www.healthcarewebwire.com/respiratory-devices-market/

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/antipsychotic-drugs-market-sizing

 To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5147

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare